Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Management of Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer

Faculty

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (NMIBC)

• Current management algorithms for NMIBC; key findings informing the selection of patients with bacillus Calmette-Guérin (BCG)-unresponsive NMIBC for pembrolizumab therapy
• Rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with BCG for BCG-naïve, high-risk NMIBC
• Available efficacy and safety data with durvalumab and sasanlimab, respectively, in combination with BCG for BCG-naïve, high-risk NMIBC
• Potential role of anti-PD-1/PD-L1 antibodies with BCG for BCG-naïve, high-risk NMIBC

MODULE 2: Perioperative Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC)

• Rationale for the evaluation of anti-PD-1/PD-L1 antibodies administered perioperatively for MIBC
• Key efficacy and safety findings documented with neoadjuvant durvalumab in combination with gemcitabine/cisplatin followed by radical cystectomy and adjuvant durvalumab monotherapy for MIBC
• FDA approval of durvalumab as a component of perioperative systemic therapy for MIBC
• Selection of appropriate candidates with MIBC for perioperative durvalumab therapy; role, if any, for patients with preexisting autoimmune conditions, compromised renal function, et cetera

MODULE 3: Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC

• Pathophysiology, spectrum, frequency, severity and timing of immune-mediated and other adverse events (AEs) observed with anti-PD-1/PD-L1 antibodies
• Impact on the tolerability of anti-PD-1/PD-L1 antibodies when administered in combination with other therapies (eg, BCG, chemotherapy, enfortumab vedotin)
• Optimal monitoring for immune-related and other potential AEs with immune checkpoint inhibitors; importance of prompt reporting of symptoms
• Recommended algorithms for the management of various immune-related AEs by grade/severity

MODULE 4: Novel Intravesical Therapies for Nonmetastatic UBC

• Advantages of intravesical delivery systems to administer systemic therapies for nonmetastatic UBC
• Available findings with the gemcitabine intravesical system for BCG-unresponsive high-risk NMIBC in patients who are ineligible for or decline radical cystectomy
• FDA approval of the gemcitabine intravesical system for the treatment of BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors; selection of appropriate candidates for this strategy
• Initial safety and efficacy results with the erdafitinib intravesical delivery system TAR-210 for patients with NMIBC and select FGFR alterations
• Ongoing Phase III evaluations of the gemcitabine intravesical system and TAR-210 for nonmetastatic UBC

MODULE 5: Tolerability/Toxicity Profile of and Other Practical Considerations with Novel Intravesical Therapies

• Importance of pretreatment evaluation of bladder integrity for patients about to receive intravesical therapy
• Logistics of insertion and removal of the gemcitabine intravesical system and TAR-210
• Incidence of urinary issues (eg, urinary frequency, urinary tract infection/pain, dysuria, micturition urgency, hematuria) related to the gemcitabine intravesical system; optimal strategies to mitigate these effects
• Spectrum, frequency and severity of systemic toxicities with the gemcitabine intravesical system (eg, myelosuppression, other laboratory abnormalities, pneumonia); appropriate monitoring and management protocols
• Incidence, severity and management of local and systemic side effects noted with TAR-210

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of urothelial bladder cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Understand the biological rationale for combining anti-PD-1/PD-L1 antibodies with bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer (NMIBC), and discuss available data with and the potential role of this approach.
• Optimize the management of high-risk NMIBC that is unresponsive to BCG, considering the efficacy and tolerability of FDA-endorsed therapies.
• Review available clinical trial evidence with novel intravesical therapies for nonmetastatic bladder cancer, and optimally incorporate these approaches into the care of appropriately selected patients with NMIBC.
• Appreciate the importance of accurately defining platinum eligibility when formulating a care plan for patients with muscle-invasive bladder cancer (MIBC), and recall the criteria that define appropriate versus inappropriate candidates for platinum-based treatment.
• Assess the biological basis for and recently presented research data with combined perioperative anti-PD-1 antibody and antibody-drug conjugate therapy for patients with MIBC and consider the current and potential clinical role of this approach.
• Analyze the scientific justification for perioperative immune checkpoint inhibitor therapy for patients with MIBC, and evaluate available data documenting the efficacy and safety of this strategy.
• Implement a plan to manage the side effects associated with approved therapies for patients with NMIBC and MIBC to support quality of life and continuation of treatment.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/BladderCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Emodi and Ms Huober have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Drakaki — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc; Contracted Research: Acrivon Therapeutics, Adcentrx Therapeutics, Allogene Therapeutics, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Infinity Pharmaceuticals Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Pfizer Inc; Data and Safety Monitoring Boards/Committees: Nektar Therapeutics; Speakers Bureaus: AstraZeneca Pharmaceuticals LP; Stock OPTIONS — Private Companies: Athos Therapeutics; Nonrelevant Financial Relationships: Dyania Health.

MODERATOR — Dr Friedlander — Advisory Committees: Aadi Bioscience, AbbVie Inc, Adaptimmune, Aktis Oncology, Astellas, Bicycle Therapeutics, Bristol Myers Squibb, Gilead Sciences Inc, Merck, Pfizer Inc, Samsung Bioepis; Consulting Agreements: Astellas, EMD Serono Inc, Genentech, a member of the Roche Group; Contracted Research: AbbVie Inc, Bicycle Therapeutics, Flare Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson, Pfizer Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Johnson & Johnson, and Merck.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.